We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




bioMérieux Acquires Microbial Genotyping Technology

By Labmedica staff writers
Posted on 03 Oct 2006
bioMérieux (Marcy-l'Etoile, France), a company specializing in in vitro diagnostics, has acquired Bacterial Barcodes (BBCI, Athens, Georgia, USA). More...
The financial terms of the acquisition were not disclosed.

BBCI is a molecular biotechnology company that developed and markets DiversiLab, a system dedicated to the field of automated microbial genotyping, offering solutions to track hospital-acquired infections (HAI) and for environmental control for product safety.

The technology automates the previously cumbersome method of strain typing and allows for better genotypic characterization of bacteria, yeast, and fungi, which helps identify the source and stop the spread of further infection. DiversiLab complements the bioMérieux suite of solutions, and together they support clinical decisions that may ultimately reduce HAIs and support the prudent usage of antibiotics.

The DiversiLab system eliminates complex manual laboratory procedures for determining the source of infections and contamination. DiversiLab allows healthcare practitioners and quality control/assurance departments to conduct investigations up to 10 times faster than previous methods. The system consists of web-based software for detection and analysis, and quality-controlled DNA fingerprinting kits (or reagents).

The technology is focused on the rapid identification of outbreak and contamination source tracking and is applicable in the hygiene market for tracking antibiotic resistant microorganisms causing hospital-acquired infections and in industrial markets for food, agricultural, pharmaceutical, and environmental contamination testing. It is also useful for characterizing biothreat agents and identifying potential outbreaks in the biodefense market.

"We are excited about the opportunity to join the industry leader in the field of infectious disease diagnostics and infection control and we feel positive about the impact our solutions can have in both the healthcare and industrial markets,” said Mimi Healy, Ph.D., president and CEO, BBCI. "The DiversiLab system perfectly complements bioMerieux's technology portfolio, which will help discriminate and track the spread and source of bacterial infections and contamination more quickly, more accurately, and more cost-effectively than other systems on the market today.”



Related Links:
bioMérieux
Bacterial Barcodes

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A simple daily blood test could help critically ill sepsis patients stop antibiotics sooner, reducing overuse and potentially helping combat antibiotic resistance (Image Credit: Adobe Stock)

Daily Blood Biomarker Testing May Help Guide Earlier Antibiotic Stopping in Sepsis

Sepsis is a life-threatening condition caused by the body’s overwhelming response to infection and accounts for thousands of deaths each year. In intensive care, concern about stopping treatment too early... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image Credit: iStock

AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps

Colorectal cancer is diagnosed in an estimated 1.9 million people worldwide each year, often without symptoms in its early stages. Timely detection of precancerous lesions is therefore important, yet some... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.